If undesired RyR1 activation gives rise to statin myopathy, the design of new statin drugs with reduced side effects would require that the functional groups of the molecule which cause RyR1 activation can be removed without disturbing its affinity for HMG‐CoA reductase. This evidence concerns the gene RYR1 and myopathy.